Lung Cancer | Specialty

Important Research Questions in Lung Cancer

December 22nd 2015

Combination Strategies in Lung Cancer

December 22nd 2015

PD-L1 Testing and Patient Selection

December 22nd 2015

Checkpoint Inhibition in NSCLC

December 22nd 2015

Measuring Immunotherapy Responses, Managing Toxicities in Lung Cancer

December 22nd 2015

Role of Immunotherapy in Oncology

December 22nd 2015

FDA Grants BI-1482694 Breakthrough Designation for T790M-Positive NSCLC

December 22nd 2015

The FDA has granted a breakthrough therapy designation to the third-generation EGFR TKI BI-1482694 as a potential treatment for patients with EGFR T790M-positive non–small cell lung cancer.

Upfront Afatinib Bests Gefitinib in Phase II Lung Cancer Study

December 22nd 2015

Frontline treatment with afatinib reduced the risk of progression or death by 27% compared with gefitinib for patients with EGFR-mutant non–small cell lung cancer.

Pembrolizumab Improves Survival in PD-L1-Positive NSCLC

December 20th 2015

Treatment with pembrolizumab reduced the risk of death by 29% compared with docetaxel for patients with PD-L1-positive non–small cell lung cancer.

Four FDA Approvals, Two Priority Reviews, and 2015 SABCS Highlights

December 17th 2015

FDA Delays Decision on Rociletinib in NSCLC

December 16th 2015

The FDA has extended the review period for rociletinib in patients with EGFR T790M-positive non–small cell lung cancer by 3 months, to allow ample time to review additional data.

FDA Approves Alectinib for ALK-Positive NSCLC

December 11th 2015

The FDA has granted an accelerated approval to alectinib as a treatment for patients with metastatic ALK-positive non–small cell lung cancer following progression on crizotinib.

FDA Grants Crizotinib Priority Review for ROS1-positive NSCLC

December 9th 2015

The FDA has granted a priority review to crizotinib as a treatment for patients with ROS1-positive metastatic non–small cell lung cancer.

Dr. Gregory Riely on Using Next-Generation Sequencing to Identify Lung Cancer Mutations

December 3rd 2015

Gregory Riely, MD Medical Oncologist, Vice Chair, Clinical Trials Office, Department of Medicine, Memorial Sloan Kettering, discusses the benefits and challenges of using next-generation sequencing to identify mutations in lung cancer.

PD-1 Inhibitors Advance Rapidly for Broad Cohort in NSCLC

December 1st 2015

As the class of agents targeting the PD-1/PD-L1 pathway expands in non–small cell lung cancer, so does the potential population of patients who would be candidates for the groundbreaking immunotherapy.

Suresh Ramalingam on Remaining Questions With Checkpoint Inhibitors in NSCLC

December 1st 2015

Suresh Ramalingam, MD, discusses the evolving role of checkpoint inhibitors in lung cancer and what challenges still remain.

Durvalumab/Tremelimumab Combo Shows Promise in NSCLC, Regardless of PD-L1 Status

December 1st 2015

Naiyer A. Rizvi, MD, discusses results of a study looking at the combination of the anti-PD-L1 immune checkpoint inhibitor durvalumab (MEDI4736) with the anti–CTLA-4 monoclonal antibody tremelimumab in patients with advanced non–small cell lung cancer.

Dr. Garon on Incorporating Immunotherapies Into Lung Cancer Treatment

November 30th 2015

dward Garon, MD, assistant professor of Medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine at University of California, Los Angeles, discusses incorporating immunotherapies into the treatment of patients with lung cancer.

Changing the Face of Lung Cancer in Kentucky: New Program May Serve as National Model

November 27th 2015

The efforts of the Kentucky LEADS Collaborative offer a unique opportunity to change the face of lung cancer in Kentucky by harnessing new lung cancer care and control strategies.

FDA Approves Necitumumab for Squamous NSCLC

November 24th 2015

The FDA has approved necitumumab in combination with gemcitabine and cisplatin for the first-line treatment of patients with locally advanced or metastatic squamous non–small cell lung cancer.